Search
Medical air
go.drugbank.com/drugs/DB09337ApprovedInvestigationalVet approvedMedical air is supplied by a special air compressor to patient care areas using clean outside air.
Technetium Tc-99m sulfur colloid
go.drugbank.com/drugs/DB09397ApprovedThis is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray.
Neratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.
Sincalide
go.drugbank.com/drugs/DB09142ApprovedIt is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK-8_. … [A261876] As the product Kinevac (FDA), sincalide is used to stimulate the duodenum, pancreas, and small bowel for cholesterol analysis, enzymatic activity analysis, and x-ray examination respectively
Triethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigationalTriethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. … [A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and
Panthenol
go.drugbank.com/drugs/DB11204ApprovedFurthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties [A32377]. … Panthenol exists as a racemic mixture containing both the dextrorotatory form (dexpanthenol) and the levorotatory form (levopanthenol).
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnIt also inhibits doxorubicinol formation in human myocardium. [3] As a result, it is believed to be less cardiotoxic while still exerting efficacy. … Pixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL.
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.
Mitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigationalwell as adjunctly to _ab externo_ glaucoma surgeries. … has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC)[L12867] - as
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin